

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att. Docket No. : REG 207A
Serial No. : to be assigned
Applicant: : Wang et al.
Date Filed : Concurrently herewith
For : METHODS OF USING IL-1
ANTAGONISTS TO TREAT
NEOINTIMAL HYPERPLASIA

Examiner : Not Yet Known
Group Art Unit : Not Yet Known

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

U.S. PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Patent Date</u>	<u>Name</u>	<u>Class/Subclass</u>	<u>Filing Date</u>
--------------------------	----------------------	--------------------	-------------	-----------------------	--------------------

FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/Subclass</u>	<u>Translation Yes</u> <u>No</u>
--------------------------	------------------------	-------------	----------------	-----------------------	----------------------------------

REG 207A
USSN to be assigned
PTO 1449 Form
Wang et al.
Page 2

OTHER DOCUMENTS

Examiner
Initials

XZ

Rectenwald et al. (2000) Circulation 102: 1697-1702

EXAMINER
CONSIDERED

DATE

Kenya L. R.

10/11/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By: Valeta Gregg

Valeta Gregg
Reg. No. 35,127
Attorneys for Applicant
Patent Agent for Applicant
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400



FORM PTO-1449

Att. Docket No. 207A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant : Wang et al.
Serial No. : 10/840,138
Date Filed : May 6, 2004
For : METHODS OF USING IL-1
ANTAGONISTS TO TREAT
NEOINTIMAL HYPERPLASIA
Examiner : To be Assigned
Group Art Unit : 1632

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

U.S. PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Patent Date</u>	<u>Name</u>	<u>Class/ Subclass</u>	<u>Filing Date</u>
XZ	5,135,917	Aug. 4, 1992	Ronald M. Burch		

FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/ Subclass</u>	<u>Translation Yes</u>	<u>No</u>
XZ	WO 00/71753 A2	30 Nov 2000	PCT			
YZ	WO 93/24134	9 Dec 1993	PCT			
XZ	WO 00/18932	06 Apr. 2000	PCT			

207A
U.S. Serial No. 10/840,138
PTO 1449 Form
Wang et al.
Page 2

X2 WO 02/16436 A2 28 Feb. 2002 PCT
X2 WO 04/022718 A2 18 Mar. 2004 PCT

OTHER DOCUMENTS

Examiner
Initials

X2 US Patent Application Publication No. US 2001/0053764 A1, Publication Date: December 20, 2001; "Interleukin-1 Inhibitors in the Treatment of Diseases".
X2 US Patent Application Publication No. US 2003/0026806 A1, Publication Date: February 6, 2003; "Antibodies and Other Selective IL-1 Binding Agents that Allow Binding to IL-1 Receptor But Not Activation Thereof".

EXAMINER
CONSIDERED

DATE

Deeghdr. 10/11/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,
By: Valeta Gregg
Valeta Gregg
Reg. No. 35,127
Attorneys for Applicant
Patent Agent for Applicant
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400